RLAY
Relay Therapeutics, Inc.
Biotechnology · Healthcare · United States
18.35
close · 2026-10-30
value
46
cheaper than peers46
quality
28
stronger fundamentals28
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | -6.2% | 61 |
| cash flow yield, latest year | -5.9% | 61 |
| earnings yield, latest year | -8.8% | 57 |
| earnings yield, 1 year ago | -12.9% | 53 |
| cash flow yield, 2 years ago | -7.6% | 52 |
| cash flow yield, 3 years ago | -5.9% | 52 |
| earnings yield, 3 years ago | -14.1% | 51 |
| earnings yield, 2 years ago | -15.2% | 51 |
| price to book | 4.51× | 37 |
| price to sales | 376.66× | 7 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 4.9% | 73 |
| return on equity | -40.0% | 60 |
| revenue growth | -60.9% | 15 |
| operating margin | -2619.7% | 10 |
4 of 4 measures available
Facts
| market cap | $4B |
| free cash flow | -$121.2M |
| employees | 193 |
| first trade | 2020-07-16 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.61 | -2.36 | -2.79 | -2.59 |
| free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M |
| net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M |
| revenue | $15.4M | $10.0M | $25.5M | $1.4M |
| unusual items | $0 | $13.2M | $6.4M | $11.7M |